Literature DB >> 167120

Efficacy of exogenous interferon treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice.

I Gresser, M G Tovey, C Bourali-Maury.   

Abstract

Initiation of treatment with potent interferon preparations (6-4 x 10-6 units per dose) 4 days after intranasal inoculation of VSV (at a time when virus has already multiplied in the brains of most mice) resulted in a marked increase in mouse survival. In a series of 6 experiments only 11 to 18% of control mice survived whereas 52% of interferon treated mice survival. These results suggest the usefulness of exogenous interferon even when treatment is begun late in the course of an acute virus disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 167120     DOI: 10.1099/0022-1317-27-3-395

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycytidylic acid-poly-L-lysine complex.

Authors:  E R Kern; G A Olsen; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

Review 2.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

3.  Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy.

Authors:  H Heremans; A Billiau; P De Somer
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

4.  Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

Authors:  Guido Wollmann; Justin C Paglino; Patrick R Maloney; Sebastian A Ahmadi; Anthony N van den Pol
Journal:  Virology       Date:  2014-11-21       Impact factor: 3.616

5.  Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus.

Authors:  J Gresser; L Morel-Maroger; P Verroust; Y Rivière; J C Guillon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

6.  Mediators of protection against lethal systemic vesicular stomatitis virus infection in hamsters: defective interfering particles, polyinosinate-polycytidylate, and interferon.

Authors:  P N Fultz; J A Shadduck; C Y Kang; J W Streilein
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

7.  Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.

Authors:  Y Rivière; I Gresser; J C Guillon; M G Tovey
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

8.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses.

Authors:  I Gresser; M G Tovey; C Maury; M T Bandu
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

Review 9.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.